Tom Ashfield is a medic with experience as a pharmacist, hospital doctor and cancer surgeon. He was previously Senior Advisor to Pfizer on antimicrobial resistance and is an elected trustee for the British Society of Antimicrobial Chemotherapy (BSAC). He guided the successful application of a novel antibacterial, active against severe drug resistant infections, within the world’s first volume de-linked payment model and now provides expertise on global market access and pull incentives.
Tom’s work has led to various UK parliamentary and Lords events and has been published widely including in Lancet and Nature journals. He currently holds fractional director level positions across policy, MedTech and HealthTech. His current work encompasses strategy, economic policy, communications, digital transformation and clinical research.